170 related articles for article (PubMed ID: 18496035)
1. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.
Bodensteiner D; Scott CR; Sims KB; Shepherd GM; Cintron RD; Germain DP
Genet Med; 2008 May; 10(5):353-8. PubMed ID: 18496035
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
[TBL] [Abstract][Full Text] [Related]
4. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on agalsidase beta in Fabry disease.
Keating GM; Simpson D
BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
8. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
9. Agalsidase Beta: a review of its use in the management of Fabry disease.
Keating GM; Simpson D
Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
[TBL] [Abstract][Full Text] [Related]
10. Successful desensitization to agalsidase beta after anaphylaxis.
Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
[No Abstract] [Full Text] [Related]
11. Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.
Tesmoingt C; Lidove O; Reberga A; Thetis M; Ackaert C; Nicaise P; Arnaud P; Papo T
Br J Clin Pharmacol; 2009 Nov; 68(5):765-9. PubMed ID: 19917001
[TBL] [Abstract][Full Text] [Related]
12. Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.
Kisinovsky I; Cáceres G; Coronel C; Reisin R
Medicina (B Aires); 2013; 73(1):31-4. PubMed ID: 23335703
[TBL] [Abstract][Full Text] [Related]
13. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
Linthorst GE; Aerts JM
J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
[No Abstract] [Full Text] [Related]
14. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
[TBL] [Abstract][Full Text] [Related]
16. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
[TBL] [Abstract][Full Text] [Related]
18. Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study.
Mignani R; Americo C; Aucella F; Battaglia Y; Cianci V; Sapuppo A; Lanzillo C; Pennacchiotti F; Tartaglia L; Marchi G; Pieruzzi F
Orphanet J Rare Dis; 2024 Feb; 19(1):38. PubMed ID: 38308295
[TBL] [Abstract][Full Text] [Related]
19. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
[TBL] [Abstract][Full Text] [Related]
20. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.
Smid BE; Rombach SM; Aerts JM; Kuiper S; Mirzaian M; Overkleeft HS; Poorthuis BJ; Hollak CE; Groener JE; Linthorst GE
Orphanet J Rare Dis; 2011 Oct; 6():69. PubMed ID: 22041095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]